Human medicines European public assessment report (EPAR): Carvykti, ciltacabtagene autoleucel, Multiple Myeloma, Date of ...
The most common side effects with Carvykti (which may affect more than 1 in 5 people) are neutropenia (low levels of neutrophils), lymphopenia and leucopenia (low levels of lymphocytes or other white blood cells), anaemia (low levels of red blood cells), …